Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASXSAT:CESSA +3.48%28 OCF Yield % is -9.16 as of Aug. 04, 2026. GuruFocus rates XSAT:CESSA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Cessatech AS ranks worse than 51.24% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cessatech AS OCF Yield % Related Terms
Cessatech AS OCF Yield % Historical Data
* Premium members only.
The historical data trend for Cessatech AS's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, Cessatech AS's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Cessatech AS's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cessatech AS (XSAT:CESSA) has a OCF Yield % of -9.16 as of Aug. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cessatech AS and its competitors. According to the industry distribution chart, Cessatech AS ranks #723 out of 1411 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Cessatech AS's OCF Yield % too high?
Cessatech AS's current OCF Yield % is -9.16. Based on the distribution chart, Cessatech AS ranks #723 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cessatech AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #723 out of 1411 companies for OCF Yield %. This places Cessatech AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cessatech AS and its competitors. Cessatech AS's current OCF Yield % is -9.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current OCF Yield % of -9.16. The current OCF Yield % is -9.16. Cessatech AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current OCF Yield % is -9.16 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score
Get the complete analysis for XSAT:CESSA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
